After a person has a stroke, the risk of having another one remains high, especially in the early stages. A stroke occurs when blood flow to part of the brain is blocked, often by a clot.
This can lead to serious damage, affecting movement, speech, and memory. Preventing another stroke is one of the most important steps in recovery.
Current treatments focus on preventing blood clots from forming. Doctors often prescribe drugs such as aspirin that reduce the ability of blood to clot. While these medications can lower risk, they are not perfect. Stronger treatments can increase the chance of bleeding, which can sometimes be dangerous or even life-threatening.
A new study has introduced a drug that may offer a better balance between safety and effectiveness. The drug, called asundexian, has shown promising results in reducing repeat strokes without increasing bleeding risk. The findings were published in The New England Journal of Medicine.
The study involved more than 12,000 patients from 37 countries. All participants had recently experienced a stroke or a mini-stroke caused by a clot not related to the heart. These types of strokes are very common.
Patients were given either asundexian or a placebo, along with standard care. They were then followed over time to see how many experienced another stroke or other serious health events.
The results showed that asundexian significantly reduced the risk of another stroke. About 6.2 percent of patients on the drug had another stroke, compared to 8.4 percent in the control group. This represents a 26 percent reduction.
The drug also lowered the risk of major cardiovascular events, including heart attacks and death. In addition, it reduced the number of severe strokes that caused disability or death.
One of the most important findings was that the drug did not increase serious bleeding. This is a major improvement over many existing treatments, which often come with this risk.
The key difference lies in how the drug works. Asundexian blocks a specific protein involved in clot formation called Factor XIa. This protein helps create harmful clots but is less involved in normal bleeding control. By focusing on this target, the drug can prevent dangerous clots while keeping the body’s natural protection against bleeding.
This new approach represents a shift in how doctors think about blood clot prevention. Instead of blocking the entire clotting system, it focuses on one part that causes harm.
However, there are still important questions to answer. The study, while large and well-designed, mainly tested the drug over a certain period. Longer-term effects are not yet fully known. The drug also needs approval from health authorities before it can be widely used.
Overall, the findings suggest that asundexian could become an important tool in stroke prevention. It may help doctors protect patients from repeat strokes without exposing them to unnecessary risks.
In summary, this study offers hope for safer treatment options. While more research is needed, the results mark a significant step forward in improving care for people at risk of stroke.
If you care about stroke, please read studies that diets high in flavonoids could help reduce stroke risk, and MIND diet could slow down cognitive decline after stroke.
For more health information, please see recent studies about antioxidants that could help reduce the risk of dementia, and tea and coffee may help lower your risk of stroke, dementia.
Source: OCEANIC-STROKE trial.
